LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing

By LabMedica International staff writers
Posted on 03 Nov 2020
Print article
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
Image: New Biomimicry Control for COVID Diagnostics Improves Accuracy and Safety of Coronavirus Testing (Photo courtesy of Wits University)
A team of researchers have developed a unique “control standard” that improves accuracy and safety of COVID-19 testing by using biomimicry as a safer alternative to incorporating the actual SARS-COV-2 virus.

Researchers at the Centre for Biomedical Tuberculosis Research at Wits University (Johannesburg, South Africa) have used the biomimicry technique to engineer a control organism that mimics the genetic material of the virus, when used in diagnostic tests kits. If the tests work correctly, the genetically modified organism is identified as being SARS-CoV-2. The control is a safe, non-pathogenic (non-disease causing), and stable. It can be rapidly deployed in a range of settings - from central laboratories to clinics. In contrast, viral-based controls require specialist shipping and handling procedures, and the need for highly-skilled staff and infrastructure.

Accuracy of testing controls is central to the deployment of any successful diagnostic test. The new control aims to fill the gap in the verification of COVID-19 tests obtained via molecular diagnosis tools, and reduce the risks and complications of using the live virus.

“The virus continues to spread viciously across countries, with infections again rising rapidly across Europe and North America,” said Professor Bavesh Kanawho headed the Wits team. “In order for governments to halt its spread, reliable tools with verifiable results are of utmost importance. Without appropriate controls to report whether tests are delivering the correct result diagnosing and effectively managing COVID-19 will be very difficult, if not impossible.”

Related Links:
Wits University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more